Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab induction therapy in Japanese subjects with moderate to severe Crohn's disease
2014-004560-38Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adalimumab in Crohn's disease (3 arms), sponsored by Abbott Laboratories. Primary endpoint: Clinical remission at Week 4.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-004560-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004560-38.